Selank: GABA-Modulating Heptapeptide — In-Vitro Research
A pharmacological overview of Selank (TKPRPGP), a synthetic analogue of tuftsin, its influence on GABA-A receptor expression, BDNF levels, and its receptor-interaction profile in preclinical research models.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TKPRPGP) developed as a stabilised analogue of the endogenous immunopeptide tuftsin. It is studied in the laboratory as a water-soluble research peptide.
Structure and identity
Selank adds a proline-rich extension to the tuftsin core, which improves its stability in solution relative to the parent peptide. It is supplied as a lyophilised powder for reconstitution under laboratory conditions.
What the research literature examines
Preclinical and in-vitro studies have examined Selank in the context of GABA-ergic signalling, BDNF expression and monoamine pathways in model systems. This research is exploratory and conducted in laboratory and animal models. Vivera Labs makes no claims regarding effects in humans; the compound is supplied strictly for in-vitro laboratory research.
Why purity matters for this peptide
Receptor- and expression-level assays are sensitive to impurities. Independent third-party HPLC analysis and a batch-specific Certificate of Analysis help ensure the peptide in the vial matches the intended sequence.
- Identity confirmed by mass spectrometry
- Purity quantified by HPLC
- Batch-specific documentation
- Lyophilised for stability
See the primary literature below for the underlying studies.
Sources
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.